RedChip Companies
|
|
Weekly Newsletter
|
|
|
| |
BIOLIFE4D recently announced its intention to file for an IPO in 2022.
|
|
The speed and success rate of new medical advances in pharmaceuticals, transplants and other vital treatments may all come down to the human heart – or, at least, a mini-heart.
That’s the message and mission of BIOLIFE4D, a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering, has bio-printed a “mini-heart” using human cells, which matches many functions of a full-size human heart and could provide medical researchers a more predictive test subject for a wide variety of new drugs, treatments and procedures to address any number of diseases and conditions.
That market opportunity alone is about $7 billion, and as BIOLIFE4D forges the potential of the mini-heart into reality, multiple markets for heart repair, heart bypass, valve replacements and eventually even full size heart transplants open up, presenting another $20 billion in cumulative market opportunities.
For more information, visit www.biolife4d.com
|
Save Foods’ Proprietary Eco Crop Protection Solution Demonstrates Up to 90% less Disease Development in Cannabis Inflorescences
Save Foods (NASDAQ: SVFD) (FSE:80W), an agri-food tech company specializing in eco crop protection that helps reduce food waste and ensure food safety, announced preliminary results from a third-party trial of its eco crop protection treatment that demonstrated up to 90 percent reduction of pathogens in cannabis inflorescences (flowers). According to a recent Forbes article, the legal cannabis market in the U.S. is expected to grow 20% to 30% annually, reaching $50 billion by 2026. Globally, the cannabis market is expected to grow from $28 billion in 2021 to $198 billion in 2028, a 32% CAGR over the forecast period, according to Fortune Business Insights.
|
Siyata Mobile Delivers FirstNet Ready(R) SD7 Device for Public Safety
Siyata Mobile Inc. (NASDAQ:SYTA, SYTAW), a global vendor of Push-to-Talk over Cellular (PoC) devices and cellular signal booster systems, announced that its SD7 ruggedized device is now certified and approved for use on FirstNet®, which allows first responders to communicate with one another easily and quickly during everyday situations, big events or emergencies.
|
|
|
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, announced that the RECOVER study is progressing well and all sites in the United States have been initiated. Global sites in Europe and India remain on track to initiate in mid-2022. RECOVER is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo.
|
Medigus Announces Record Fiscal Year 2021 Financial Results
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, today reported financial results for the fiscal year ended December 31, 2021. Highlights included Record Revenues of $10.1 million that represented a 1,805% increase over 2020, a 47% gross margin and 40% net margin and $4 million net income for the full year, up from a net loss of $6.9 million in 2020.
|
|
|
| Upcoming Events |
|
|
|
| NASDAQ: ARDS - Aridis Pharmaceuticals |
| 4:15pm Eastern |
| Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. |
|
|
|
|
|
| NASDAQ: MDGS - Medigus Ltd |
| 10:00am Eastern |
| Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. |
|
|
|
|
|
| NASDAQ: RVSN - Rail Vision |
| 4:15pm Eastern |
| Rail Vision is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electrooptic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions. |
|
| Archive Events |
|
|
|
| NASDAQ: MTEK - Maris-Tech |
| Meeting Duration 23 minutes |
| Maris-Tech is a leading B2B provider of intelligent video transmission technology, founded by veterans of the Israel technology sector with extensive electrical engineering and imaging experience. |
|
|
|
|
|
| OTC: YAYO - EVmo Inc. |
| Meeting Duration 27 minutes |
| EVmo, Inc. bridges the gap between rideshare drivers in need of a suitable vehicle and rideshare companies that depend on attracting and keeping drivers. |
|
|
|
|
|
| NASDAQ: BIVI - BioVie |
| Meeting Duration 34 minutes |
| BioVie Inc. is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. |
|
|
|
|
|
| NASDAQ: RNAZ - TransCode Therapeutics |
| Meeting Duration 44 minutes |
| TransCode Therapeutics is developing therapeutic and diagnostic candidates designed to deliver on the promise of RNA in oncology. |
|
|
Lesson of the Week
Management is the first fundamental to consider when evaluating smaller-cap companies.
|
|
|
MidSouth Week in Review
Last week's Fed rate hike was the largest since 2000 and is in response to burgeoning inflation.
|
|
|
You are receiving this email because your email is subscribed to our mailing list.
Click here to unsubscribe your email address from this list.
Copyright © 2022. All rights reserved.
|
|
© 2022 RedChip , All rights reserved
|
|
| |
|
|
|
